Inhibits both type I and type II isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT). Reduces serum DHT by >90% (vs ~70% for finasteride which only blocks type II). Used for benign prostatic hyperplasia and androgenic alopecia.
Half-Life (t½)
PO: 840h
Dosing Guidelines
PO: Typical 0.5 mg (Range: 0.5–0.5 mg)
Target Organ Systems
endocrine
reproductive
integumentary
Interactions
Finasteride (warn): alternative 5α-reductase inhibitor — don't combine, therapeutic redundancy
Pathways It Modulates
Androgenetic alopecia (inhibitor) — SRD5A1 + SRD5A2 — pan-5αR; >90% DHT block; off-label for AGA in US